Abstract |
Infections caused by resistant Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) are now posing a major health risk for patients in hospital and community settings. There is a need to evaluate new antibiotics that would offer reliable clinical efficacy combined with a favorable safety profile for the treatment of such infections. Ceftaroline is a new member of the cephalosporin class of antibiotics with expanded activity against Gram-positive pathogens such as MRSA, vancomycin-intermediate S. aureus, vancomycin-resistant S. aureus and multidrug-resistant Streptococcus pneumoniae, while retaining good activity against common Gram-negative organisms. Phase II and III studies have shown ceftaroline to be an effective and well-tolerated treatment for complicated skin and skin-structure infections compared with standard therapy. Trials are ongoing in the treatment of community-acquired pneumonia.
|
Authors | Zeina A Kanafani, G Ralph Corey |
Journal | Future microbiology
(Future Microbiol)
Vol. 4
Issue 1
Pg. 25-33
(Feb 2009)
ISSN: 1746-0921 [Electronic] England |
PMID | 19207097
(Publication Type: Journal Article, Review)
|
Chemical References |
|
Topics |
- Adult
- Animals
- Cephalosporins
(administration & dosage, adverse effects, pharmacology, therapeutic use)
- Clinical Trials, Phase II as Topic
- Clinical Trials, Phase III as Topic
- Gram-Positive Bacterial Infections
(drug therapy, microbiology)
- Gram-Positive Cocci
(drug effects)
- Humans
- Mice
- Skin Diseases, Bacterial
(drug therapy, microbiology)
- Treatment Outcome
|